BridgeBio Pharma up on dwarfism therapy trial data

Hanall Biopharma

20/06/2023 17:30

** BridgeBio Pharma Inc shares  BBIO.O  up 8.4% at $16.30
    ** Company reports positive updated 6-months data from a
patient group in mid-stage trial for its investigational
therapy, infigratinib, for a form of dwarfism 
    ** Co is developing therapy as a potential treatment for
achondroplasia, which is a form of disproportionate short
stature caused by mutation in a gene that regulates bone growth
    ** Treatment showed a mean increase of 3.38 cm/year in
annualized height velocity in children and was well tolerated,
with no serious adverse events - company   
    ** BBIO's orally administered therapy is expected to compete
with BioMarin Pharmaceutical Inc's  BMRN.O  approved daily
injectable drug Voxzogo for the disease
    ** Shares of BMRN down 1.4% at nearly $95
    ** YTD, BBIO stock more than doubled in value, including
session's gain 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))